UK Competition Watchdog Targets Four Firms Over Seven-Fold Prochlorperazine Price Hike
Executive Summary
The UK CMA alleges that four companies were involved in a non-compete agreement that resulted in a 700% increase in the cost to the NHS of a generic medicine for nausea and dizziness.
You may also be interested in...
UK Competition Body Steps Up Generic Hydrocortisone Probe
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.